First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study.

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Ferdinandos Skoulidis, Kristof Cuppens, Willemijn S.M.E. Theelen, Caicun Zhou, Enriqueta Felip, Jung Seop Eom, Jennifer Elisabeth Friedmann, Gennaro Daniele, Rajwanth Veluswamy, Benjamin J. Solomon, Teresa Morán, Flávio Augusto Ferreira da Silva
+8 more Karina Vera, Mariah Mayo, Ahmadur Rahman, Shuai Li, Hen Prizant, Chipman R. Stroud, Christoph Meyenberg, Adrian G. Sacher
DOI: 10.1200/jco.2026.44.16_suppl.8510
Cited by: 1

Abstract

8510 Background: Krascendo 170 (NCT05789082) is an open-label, phase Ib/II, dose-finding and -expansion study of divarasib, an oral next-generation KRAS G12C inhibitor, with/without other anti-cancer therapies in 1L KRAS G12C + NSCLC. We report the primary analysis for pts receiving divarasib plus pembro in the programmed death-ligand 1 (PD-L1)-positive cohort (tumor cell [TC] ≥1%; cohort A1) and key preliminary data for the PD-L1-negative cohort (TC

Fields of Study & Subjects

Melanoma and MAPK Pathways Phagocytosis and Immune Regulation Lung Cancer Treatments and Mutations

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
8510–8510
Publication date
28 May 2026
Language
EN